Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, texture, and function.

Curtis A. Cluff, Chief Executive Officer of Envy Medical said, “This is the first time in Envy's history that we have taken on outside growth capital, and we did so with unanimous board and shareholder support. That support is due in large part to HCP's business acumen and an understanding that they bring significant experience to the table as Envy accelerates growth towards becoming a major global player in the specialized skincare market."

Envy's products include SilkPeel®, a device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive global licensor of skin brightening peptides including Lumixyl®.

Envy plans to continue its commitment in developing cutting edge aesthetic and therapeutic skincare offerings, as well as other medical skincare professionals and their patients.

Go to: www.envymedical.com for more information.